Le Lézard
Classified in: Health, Business
Subject: CON

Comagine Health Selected as Prime Awardee of the Network of Quality Improvement and Innovation Contractor by the Centers for Medicare & Medicaid Services


SALT LAKE CITY, June 14, 2019 /PRNewswire-PRWeb/ -- The Centers for Medicare & Medicaid Services selected Comagine Health as a Prime awardee of the Network of Quality Improvement and Innovation Contractor. As a Prime NQIIC awardee partnering with other Quality Improvement contractors under the new CMS Indefinite Delivery/Indefinite Quantity (IDIQ) contract mechanism to support quality improvement efforts, each NQIIC may serve as:

As a NQIIC awardee, Comagine Health has demonstrated healthcare quality improvement expertise. Services supported by some of the NQIIC awardees may include:

About Comagine Health

Comagine Health, formerly Qualis Health and HealthInsight, works collaboratively with patients, providers, payers and other stakeholders to reimagine, redesign and implement sustainable improvements in the health care system. As a trusted, neutral party, we work in our communities to address key, complex health and health care delivery problems. In all our engagements and initiatives, we draw upon our expertise in quality improvement, care management, health information technology, analytics and research. We invite our partners and communities to work with us to improve health and redesign the health care delivery system. For more information, please visit comagine.org.

 

SOURCE Comagine Health


These press releases may also interest you

at 19:00
The "Global Dermatology Partnering 2014-2019: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global Dermatology Partnering 2014-2019: Deal trends, players and financials report provides an...

at 19:00
During the Belgian Economic Mission to the People's Republic of China, Eppen and Syngulon have signed in Beijing on November 18 a MOU (Memorandum of Understanding) for the development of a new generation of feed probiotics leveraging bacteriocins as...

at 18:45
The "Global Cardiovascular Partnering 2014-2019: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global Cardiovascular Partnering 2014 to 2019 provides the full collection of Cardiovascular disease...

at 18:30
The "Global Autoimmune Partnering 2014-2019: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global Autoimmune Partnering 2014 to 2019 provides the full collection of Autoimmune disease deals signed...

at 18:15
The "Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2019" report has been added to ResearchAndMarkets.com's offering. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and...

at 18:10
SK Biopharmaceuticals, Co., Ltd., an innovative global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, and its U.S. subsidiary SK Life Science, Inc. announced today that the...



News published on 14 june 2019 at 18:00 and distributed by: